
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Abbott Laboratories, which manufactures Collagenase Santyl Ointment, will take over U.S. marketing of the product through its Ross Products Division beginning Jan. 1.